Is Semaglutide Legal in Ireland? What the HPRA Actually Authorises

The three authorisations — and the one firm boundary

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking endogenous GLP-1, a hormone released from intestinal L-cells in response to food. That mechanism has produced three distinct, licensed pharmaceutical products, each with its own indication and its own marketing authorisation issued at EU level by the European Medicines Agency (EMA). In Ireland, those EMA authorisations are recognised directly by the Health Products Regulatory Authority (HPRA), which is the competent national authority responsible for the regulation of medicines and medical devices on Irish territory.

Understanding semaglutide's legal status in Ireland requires knowing which of these three authorisations applies to which product, and then understanding what sits entirely outside all three.

Wegovy (semaglutide 2.4 mg subcutaneous) — available in Ireland from March 2025

Wegovy is a once-weekly subcutaneous injection of semaglutide at a dose of 2.4 mg, indicated as an adjunct to a reduced-calorie diet and increased physical activity for the management of weight in adults with an initial body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity. The EMA granted Wegovy its EU marketing authorisation in January 2022, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) based substantially on data from the STEP clinical programme — a series of randomised controlled trials evaluating semaglutide against placebo in adults with obesity. The pivotal STEP 1 trial, published in The New England Journal of Medicine in 2021 (Wilding et al., PMID 33567185), demonstrated a mean body weight reduction of approximately 15% over 68 weeks in the semaglutide group.

Despite holding a valid EU marketing authorisation from 2022, Wegovy did not become commercially available in Ireland until March 2025. This gap is not unusual: a product can receive regulatory approval while the marketing authorisation holder has not yet completed national reimbursement negotiations, supply-chain arrangements, or local registration steps. Once available, Wegovy is a prescription-only medicine (POM) in Ireland — a patient cannot legally obtain it without a valid prescription from a licensed healthcare professional, nor can a pharmacist dispense it without one. The EMA's full European Public Assessment Report (EPAR) for Wegovy is available at ema.europa.eu.

Ozempic (semaglutide 0.5 mg and 1 mg) — a separate authorisation for type 2 diabetes

Ozempic is a once-weekly subcutaneous injection of semaglutide at lower doses (0.5 mg and 1 mg), indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults. It received its EU marketing authorisation in February 2018. In Ireland, Ozempic is dispensed against a prescription for type 2 diabetes and is a separately approved product from Wegovy, despite sharing the same active molecule. Its EMA EPAR is available at ema.europa.eu. The two products have different therapeutic indications, different approved doses, and different regulatory histories — they are not interchangeable under Irish medicines law simply because they contain the same peptide.

Oral semaglutide (Rybelsus) — authorised for diabetes, but not for weight management

Rybelsus is an oral formulation of semaglutide approved by the EMA in September 2020 for the treatment of type 2 diabetes mellitus. It is not approved in the EU for chronic weight management. An oral formulation of semaglutide for obesity — under separate development at higher doses — had not received EU marketing authorisation as of mid-2026. This is a distinction worth stating clearly: the existence of one approved oral semaglutide product does not mean that oral semaglutide for weight loss is available or authorised in Ireland. These are separate regulatory applications requiring separate evidence packages evaluated independently by the CHMP.

How the HPRA's classification system works

The Health Products Regulatory Authority is Ireland's national competent authority under EU medicines law. It operates within the framework set by Directive 2001/83/EC of the European Parliament and Council, as transposed into Irish law primarily through the Medicinal Products (Control of Placing on the Market) Regulations and related statutory instruments. Ireland's membership of the European Union means that EU-level marketing authorisations granted by the European Commission — following EMA opinions — are valid across all member states, including Ireland, without further national approval being required.

The HPRA maintains the Irish Medicines Board's legacy registers and publishes product information, including summaries of product characteristics and package leaflets, through its online medicines database at hpra.ie. The agency also classifies medicinal products according to whether they require a prescription (prescription-only medicines, designated POM in Ireland) or are available over the counter. All three licensed forms of semaglutide — Wegovy, Ozempic, and Rybelsus — are classified as prescription-only medicines in Ireland. This means that supply to a patient is lawful only when a registered prescriber has issued a valid written prescription and a licensed pharmacist has dispensed the product against it.

The classification as prescription-only is not an administrative formality. It reflects the CHMP's assessment that these products have a sufficiently narrow therapeutic window, require individual clinical judgment to prescribe appropriately, and carry risks that necessitate medical supervision. The prescription requirement serves the patient; it is not a barrier to be circumvented.

No state reimbursement: the financial reality in 2026

Holding a marketing authorisation is a necessary but not sufficient condition for a medicine to be available to Irish patients at subsidised cost through the public health system. Reimbursement decisions — whether a medicine will be funded under the General Medical Services (GMS) scheme for medical card holders, or covered up to a monthly co-pay limit under the Drugs Payment Scheme (DPS) — are made separately by the Health Service Executive (HSE) following a health technology assessment process.

As of 2026, Wegovy is not reimbursed under the GMS scheme or the Drugs Payment Scheme. A patient who obtains a valid private prescription for Wegovy pays the full retail price out of pocket. This places the medicine beyond the practical reach of many patients who might clinically benefit from it, regardless of the regulatory authorisation. The situation is not unique to Ireland: the same tension between regulatory approval and reimbursement access has played out across multiple EU member states in the years since the EMA granted Wegovy its marketing authorisation.

Reimbursement decisions can change if new health technology assessments are completed or if manufacturers agree to confidential pricing arrangements with the HSE. Readers should verify the current reimbursement status directly with the HSE or their prescribing clinician, as this is the aspect of semaglutide's availability in Ireland most likely to evolve.

What the HPRA has seized: the unlicensed market and its risks

The existence of a high-demand, prescription-only medicine for which many patients face cost or access barriers has, predictably, produced a parallel unlicensed market. The HPRA has been explicit about this. In successive enforcement communications and public warnings, the agency has documented seizures of injectable products purporting to contain semaglutide, tirzepatide, or related GLP-1 compounds — units sourced from unlicensed suppliers, many circulating as counterfeit or substandard versions of branded medicines, and some consisting of raw peptide powder or pre-filled vials carrying no recognised marketing authorisation.

The aggregate number of illegal units seized by the HPRA and associated enforcement agencies across these operations runs into the tens of thousands. This is not a marginal enforcement footnote. It represents a deliberate and sustained attempt to bring an unlicensed category of injectable medicines under control — because the risks associated with uncharacterised injectables are not theoretical. A vial sold as semaglutide without a valid marketing authorisation may contain the correct molecule at an uncertain purity, the wrong molecule, a dangerous impurity, or nothing meaningful at all. There is no independent Certificate of Analysis requirement attached to unlicensed supply; there is no batch recall system; there is no pharmacovigilance network to detect harm after the fact.

The HPRA publishes product alerts and safety notices on its website. Anyone who encounters an injectable product claiming to contain semaglutide and sourced outside a licensed pharmacy should treat it as potentially counterfeit or unlicensed, and report it to the HPRA directly.

The legal boundary, precisely drawn

Ireland's medicines legislation, derived from EU Directive 2001/83/EC and implemented through domestic statutory instruments, makes it unlawful to place a medicinal product on the Irish market without a valid marketing authorisation — unless a specific exemption applies, such as a hospital preparation or a named-patient special import. A medicinal product is defined in EU law not only by its composition but also by its presentation: a substance is treated as a medicinal product if it is presented as having therapeutic properties, regardless of whether it actually does. A product containing semaglutide peptide that is presented or promoted as a weight-loss treatment — whatever its packaging calls it — falls within the scope of medicines regulation in Ireland.

Raw semaglutide peptide, research-grade semaglutide, unlicensed injectable semaglutide sold online: none of these hold a marketing authorisation. Supplying them for human use in Ireland is not a regulatory grey area. It is a breach of medicines legislation, and the HPRA's enforcement record makes clear that it is treated as such. The prescription-only boundary applies to the molecule in all its forms when the intended use is human therapeutic administration — not just to the three branded products that have gone through the authorisation process.

A note on research use

Research conducted under formal clinical trial authorisations — granted by the HPRA under Regulation (EU) No 536/2014 on clinical trials — can involve investigational medicinal products, including peptides, that do not hold marketing authorisations. This is an entirely different legal pathway, subject to independent ethical review, competent authority approval, informed consent requirements, and GMP-standard manufacturing of the investigational product. It is not a route that applies to individual purchases of unlicensed injectables. The existence of legitimate clinical research involving unlicensed compounds does not alter the legal position of the supply described above.

Summary: what the HPRA actually authorises

Semaglutide is legal in Ireland in three specific, licensed forms: injectable Wegovy for weight management (available from March 2025, prescription-only, no state reimbursement as of 2026); injectable Ozempic for type 2 diabetes (authorised since 2018, prescription-only); and oral Rybelsus for type 2 diabetes (authorised since 2020, prescription-only). Oral semaglutide for chronic weight management is not yet authorised in the EU.

Outside of these three licensed forms, semaglutide in any presentation — raw peptide, unlicensed injectable, online-sourced vial — is not authorised for human use in Ireland. The HPRA has conducted sustained enforcement operations against this unlicensed market and has seized tens of thousands of units. The legal boundary is not ambiguous: it is drawn at the marketing authorisation, enforced through prescription-only supply requirements, and backed by active regulatory oversight.

For a reader who wants to understand the HPRA's classification framework in the wider context of Ireland's medicines regulation, the authoritative source is the agency's own published guidance and its medicines database at hpra.ie.